EpCAM has proved to be a target with high sensitivity (100%) and specificity (100%) for lymph node metastases and high sensitivity (95%) and specificity (100%) for bone metastases. This evidence concerns the gene EPCAM and metastatic malignant neoplasm in the lymph nodes.